Jonathan M. Rourke

Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention.

Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention.

Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention.

Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention.

Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention.

Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention.